April 7, 2022: Event program

To accommodate our global audience, live presentations will be held over a 24-hour period in three live sessions. Please consult this program for talks in your time zone.

In addition to the listed live presentations, enjoy access to dozens of on-demand presentations from past OncomineWorld events, visit virtual laboratories to learn about the many applications of genomic profiling in precision oncology research, and explore interactive and educational virtual features.

Asia Pacific Live Session 1: 12:00–14:40 p.m. SGT

Welcome:
Luca Quagliata, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: 12:00–12:05 p.m. SGT

Part 1: General education
Lung pathology in the era of targeted therapies in patients with advanced NSCLC: Dr. Trishe Leong, Medical Director of Pathology and Director of Anatomical Pathology, St. Vincent’s Hospital Melbourne, 12:05–12:25 p.m. SGT

Part 2: Companion diagnostic testing
Exploratory factors relevant to success of the Ion Torrent™ Oncomine™ Dx Target Test: Dr. Rie Sakakibara, Assistant Professor, Department of Respiratory Medicine, Tokyo Medical and Dental University, 12:25–12:45 p.m. SGT

Experience of ROS1 CDx platforms in the central laboratory of South Korea: Dr. Tae-Jung Kim, Director of Pathology, Yeouido St. Mary’s Hospital, 12:45–13:05 p.m. SGT

Q&A: 13:05–13:20 p.m. SGT

Break: 13:20–13:30 p.m. SGT

Part 3: Clinical oncology research
Peter MacCallum Cancer Centre validation of the Oncomine™ Precision Assay and experience with the Ion Torrent™ Genexus™ System: Dr. Chelsee Hewitt, Peter MacCallum Cancer Centre, 13:30–14:00 p.m. SGT

Q&A: 14:00–14:10 p.m. SGT

Genexus System virtual demo with live Q&A: 14:10–14:40 p.m. SGT
Europe and the Americas Live Session 2: 15:00–17:30 p.m. CET

Welcome:
Luca Quagliata, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: 15:00–15:05 p.m. CET

Part 1: General education
RET aberrations and \( \text{EGFR} \) exon 20 insertions testing in the complex NSCLC biomarker landscape: Dr. Fernando López-Ríos, MD, PhD, Department of Pathology, Doce de Octubre University Hospital Madrid, 15:05–15:25 p.m. CET

Part 2: IVDR update
An update on IVDR implementation plans and the Thermo Fisher Scientific NGS IVDR product pipeline: Dr. Jon Sherlock, Director of Product Management, Oncology; and Anna Sadio, Regulatory Manager, Thermo Fisher Scientific, 15:25–15:45 p.m. CET

Q&A: 15:45–16:00 p.m. CET
Break: 16:00–16:10 p.m. CET

Americas Live Session 3: 12:00–14:30 p.m. PT

Welcome:
Luca Quaglia, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: 12:00–12:05 p.m. PT

Part 1: General education
\( \text{HER2} \) mutation—an emerging biomarker in NSCLC: Matthew Beer, Medical Affairs Director, Thermo Fisher Scientific, 12:05–12:25 p.m. PT

Q&A: 12:25–12:35 p.m. PT
Break: 12:35–12:35 p.m. PT

Part 2: Clinical oncology research
Analytical validation of a next-generation sequencing laboratory-developed test: John Williamson, Sr. Technical Project Manager; and Rafael D. Ramirez, Global Business Development Manager, Thermo Fisher Scientific, 12:35–12:55 p.m. PT

Rapid next-generation sequencing for the study of acute myeloid leukemia: Dr. Diana Morlote, Assistant Professor, Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham, 13:05–13:25 p.m. PT

Ion Torrent™ Oncomine™ Precision Test on the Genexus System—first experience: Dr. Daria Grafodatskaya, Assistant Professor Pathology and Molecular Medicine, McMaster University Hamilton, 13:25–13:45 p.m. PT

Q&A: 13:45–14:00 p.m. PT
Genexus System virtual demo with live Q&A: 14:00–14:30 p.m. PT

Learn more and register at labroots.com/ms/virtual-event/oncomineworld-2022

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL117376 0222